Perioperative Dexamethasone Reduces Postoperative Pain and Nausea After Periacetabular Osteotomy

Sponsor
Balgrist University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05120076
Collaborator
(none)
60
1
2
25.5
2.4

Study Details

Study Description

Brief Summary

The purpose of this study is to assess the effect of Dexamethasone on postoperative pain and nausea after periacetabular osteotomy.

Condition or Disease Intervention/Treatment Phase
  • Drug: Dexamethasone 4 Mg/mL Injectable Solution
  • Drug: NaCl 0.9%
Phase 3

Detailed Description

Bernese periacetabular osteotomy (PAO) is a standard procedure with good mid and long-term results. Postoperative pain is a great concern and postoperative pain management of great importance. High demand for opiates and the associated side effects especially nausea limit the postoperative rehabilitation.

Promising results to reduce postoperative pain and nausea have been achieved by perioperative dexamethasone, which has a strong anti-inflammatory effect reducing pain and inflammation as well as a strong anti-emetic effect, especially in total hip replacement.

It is our goal to compare the effect of perioperative intravenous dexamethasone (3x 4mg Amp. Fortecortin =12mg prior to surgery and 3x4mg Amp. Fortecortin = 12mg at 8.00am of the first postoperative day) to a control group (placebo) (3ml saline solution postoperative day 1 at 8.00am) regarding pain level, opiate consumption, postoperative nausea and patient satisfaction.

A double-blinded prospective randomized control trial including up to 60 patients receiving elective unilateral PAO will be conducted.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Masking Description:
Only the investigators as well as the head of anasthesiology will be informed.
Primary Purpose:
Treatment
Official Title:
Perioperative Dexamethasone Reduces Postoperative Pain and Nausea After Periacetabular Osteotomy- a Double-blinded Placebo Controlled RCT
Actual Study Start Date :
Jul 16, 2021
Anticipated Primary Completion Date :
Jul 31, 2023
Anticipated Study Completion Date :
Aug 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Dexamethasone group

The patients in the dexamethasone group will receive 12mg dexamethasone (Fortecortin ®) intravenously 15-60 minutes prior to surgery while in general anasthesia as well as 12mg dexamethasone intravenously (Fortecortin®) on the first postoperative day at approx. 8.00a.m. by the investigators.

Drug: Dexamethasone 4 Mg/mL Injectable Solution
s. arm/group description
Other Names:
  • Fortecortin Inject (Merck (Switzerland))
  • Placebo Comparator: Placebo/ Control group

    The patients will not receive any additional drugs preoperatively. 3ml of a 0.9% NaCl Solution (NaCl B. Braun Inf Lös 0.9 % 250ml Ecoflac plus®) will be administered at approx. 8.00 a.m. on the first postoperative day by the investigators.

    Drug: NaCl 0.9%
    s. arm/group description
    Other Names:
  • NaCL Braun (B Braun medical)
  • Outcome Measures

    Primary Outcome Measures

    1. Postoperative pain level [6 hours postoperatively]

      The VAS Pain score assesses pain Levels on a scale from 0 (no pain) to 10 (worst possible pain).

    2. Postoperative pain level [24 hours postoperatively]

      The VAS Pain score assesses pain Levels on a scale from 0 (no pain) to 10 (worst possible pain).

    3. Amount of opiates (morphinequivalent) consumed [48 hours postoperatively]

      The authors will assess the amount of Opiates the Patient needed due to the performed Surgery during the hospital stay.

    4. Amount of anti-emetics consumed (Ondansetron) [48 hours postoperatively]

      The authors will assess the amount of mg of anti- emetic drugs (Ondansetron) the Patient required during the Hospital stay.

    Secondary Outcome Measures

    1. Patient satisfaction as assessed by the revised American pain society patient outcome questionnaire [6 hours postoperatively]

      Patient satisfaction will be assessed by the revised American pain Society Patient Outcome questionnaire (APS-POQ-R). (0% worst, 100% best)

    2. Patient satisfaction as assessed by the revised American pain society patient outcome questionnaire [24 hours postoperatively]

      Patient satisfaction will be assessed by the revised American pain Society Patient Outcome questionnaire (APS-POQ-R).(0% worst, 100% best)

    3. Patient satisfaction as assessed by the revised American pain society patient outcome questionnaire [48 hours postoperatively]

      Patient satisfaction will be assessed by the revised American pain Society Patient Outcome questionnaire (APS-POQ-R).(0% worst, 100% best)

    4. Number of vomiting events [48 hours postoperatively]

      The authors will count the number of vomiting events postoperatively as a direct marker for postoperative Nausea.

    5. Physical therapy milestones 1 [1 week postoperatively]

      First steps in the hallway

    6. Physical therapy milestones 2 [1 week postoperatively]

      Walk up stairs

    7. Physical therapy milestones 3 [1 week postoperatively]

      Bicycle ergometer can be used indipendently by the patient

    8. Length of hospitalization [2 weeks]

      The length of hospitalization will be obtained from the Patient Chart.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age ≥ 18 years

    • General anasthesia

    • Elective periacetabular osteotomy for any reason

    • Written informed consent as documented by signature (Appendix Informed Consent Form)

    • Competent German language skills

    Exclusion Criteria:
    • Chronic pain patient, chronic lower back pain

    • Steroid or immunosuppressive drugs used within 6 months of surgery

    • Renal failure, hepatic failure

    • Relevant allergies

    • Pregnancy/ Breast feeding

    • Contraindications for Fortecortin treatment according to Swissmedic

    • Previous enrollment into the current study

    • Participation in another study with investigational drug within the 30 days preceding and during the present study

    • Known or suspected non-compliance, drug or alcohol abuse Illness according to "Warnings and Precautions of Dexamethasone and NaCl"

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Uniklinik Balgrist Zürich Switzerland 8008

    Sponsors and Collaborators

    • Balgrist University Hospital

    Investigators

    • Principal Investigator: Patrick Zingg, MD, Study Principal Investigator

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Balgrist University Hospital
    ClinicalTrials.gov Identifier:
    NCT05120076
    Other Study ID Numbers:
    • DEXA and PAO
    First Posted:
    Nov 15, 2021
    Last Update Posted:
    Apr 6, 2022
    Last Verified:
    Jul 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 6, 2022